Quick Answer
HOOKIPA Pharma Inc. reported Total Revenue of $43.95 million for fiscal year 2024.
HOOKIPA Pharma Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $43.95M +118.3% |
$20.13M +41.3% |
$14.25M -22.8% |
$18.45M -5.8% |
$19.58M +64.0% |
$11.94M +56.5% |
| Revenue (ASC 606) | $43.95M +118.3% |
$20.13M +41.3% |
$14.25M -22.8% |
$18.45M -5.8% |
$19.58M +64.0% |
$11.94M +56.5% |
| Net Income | -$43.50M +46.7% |
-$81.58M -25.7% |
-$64.92M +14.2% |
-$75.67M -71.6% |
-$44.08M -2.4% |
-$43.04M -165.1% |
| Diluted EPS | -$3.47 +59.8% |
-$8.63 +12.9% |
-$9.91 -330.9% |
-$2.30 -36.1% |
-$1.69 +29.9% |
-$2.41 |
| Total Assets | $82.55M -48.8% |
$161.34M -5.3% |
$170.45M +35.2% |
$126.05M -32.9% |
$187.82M +30.7% |
$143.75M +110.6% |
| Cash and Equivalents | $39.68M -66.1% |
$117.10M +4.1% |
$112.49M +70.6% |
$65.92M -53.8% |
$142.74M +26.2% |
$113.15M +132.9% |
| Stockholders Equity | $51.21M -43.0% |
$89.86M -12.3% |
$102.52M +14.4% |
$89.59M -42.6% |
$156.12M +32.4% |
$117.90M +295.3% |
| R&D Expense | $68.51M -20.7% |
$86.42M +25.9% |
$68.64M -17.1% |
$82.85M +51.2% |
$54.79M +18.3% |
$46.31M +110.8% |
| Operating Income | -$51.45M +47.3% |
-$97.69M -33.5% |
-$73.16M +10.4% |
-$81.67M -53.3% |
-$53.28M -4.3% |
-$51.09M -141.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2025 | $2.00M | -94.5% | -57.4% |
| Revenue (ASC 606) | March 31, 2025 | $2.00M | -94.5% | -57.4% |
| Net Income | March 31, 2025 | -$15.43M | -207.3% | -11.5% |
| Diluted EPS | March 31, 2025 | -$1.23 | -207.9% | -11.8% |
| Total Assets | March 31, 2025 | $61.26M | -58.0% | -25.8% |
| Cash and Equivalents | March 31, 2025 | $40.28M | -56.6% | +1.5% |
| Stockholders Equity | March 31, 2025 | $34.08M | -67.4% | -33.5% |
| R&D Expense | March 31, 2025 | $12.86M | -36.2% | -17.4% |
| Operating Income | March 31, 2025 | -$17.87M | -260.9% | +4.1% |
| Shares Outstanding | June 30, 2019 | 21.59M | — | +2044.7% |
- HOOKIPA Pharma Inc. reported Total Revenue of $43.95 million for fiscal year 2024.
- HOOKIPA Pharma Inc. showed an increase of +118.3% in Total Revenue compared to the prior fiscal year.
- HOOKIPA Pharma Inc. reported Revenue (ASC 606) of $43.95 million for fiscal year 2024.
- HOOKIPA Pharma Inc. showed an increase of +118.3% in Revenue (ASC 606) compared to the prior fiscal year.
- HOOKIPA Pharma Inc. reported Net Income of -$43.50 million for fiscal year 2024.
- HOOKIPA Pharma Inc. showed an increase of +46.7% in Net Income compared to the prior fiscal year.
- HOOKIPA Pharma Inc. reported Diluted EPS of $3.47 per share (loss) for fiscal year 2024.
- HOOKIPA Pharma Inc. showed an increase of +59.8% in Diluted EPS compared to the prior fiscal year.
- HOOKIPA Pharma Inc. reported Total Assets of $82.55 million for fiscal year 2024.
- HOOKIPA Pharma Inc. showed a decrease of -48.8% in Total Assets compared to the prior fiscal year.
- HOOKIPA Pharma Inc. reported Cash and Equivalents of $39.68 million for fiscal year 2024.
- HOOKIPA Pharma Inc. showed a decrease of -66.1% in Cash and Equivalents compared to the prior fiscal year.
- HOOKIPA Pharma Inc. reported Stockholders Equity of $51.21 million for fiscal year 2024.
- HOOKIPA Pharma Inc. showed a decrease of -43.0% in Stockholders Equity compared to the prior fiscal year.
- HOOKIPA Pharma Inc. reported R&D Expense of $68.51 million for fiscal year 2024.
- HOOKIPA Pharma Inc. showed a decrease of -20.7% in R&D Expense compared to the prior fiscal year.
- HOOKIPA Pharma Inc. reported Operating Income of -$51.45 million for fiscal year 2024.
- HOOKIPA Pharma Inc. showed an increase of +47.3% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: